Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Graft vs Host Disease 1

Interventions

venetoclax 73Specimen Handling 66Cyclophosphamide 58Cytarabine 50Biopsy 49fludarabine 42Azacitidine 37Rituximab 28fludarabine phosphate 21blinatumomab 20Methotrexate 20Magnetic Resonance Spectroscopy 20Daunorubicin 20Vincristine 19Prednisone 18ibrutinib 16Injections 16Dexamethasone 16decitabine and cedazuridine drug combination 15Whole-Body Irradiation 15Tacrolimus 14Melphalan 14Doxorubicin 14Busulfan 14obinutuzumab 13acalabrutinib 13Mycophenolic Acid 13Granulocyte Colony-Stimulating Factor 13merphos 12Mercaptopurine 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Emapalumab × Other hematologic neoplasm × 30 days × Clear all
NCT06996119 2026-05-11

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

City of Hope Medical Center

Phase 1 Recruiting
15 enrolled
MyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡